Quince Therapeutics, Inc. (QNCX) Scorecard
- 2026-Q2: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth No data; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth No data; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth No data; EPS growth Win.
17/42
2.0 / 5 stars
All 42 Win/Lose results and 78 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 4 wins, 4 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/2 |
LoseQNCX / S&P -9.95% / 15.20% |
No dataQNCX / S&P / 15.00% |
LoseQNCX / S&P -85.62% / 50.40% |
| 2026-Q11/2 |
LoseQNCX / S&P -96.99% / -4.33% |
No dataQNCX / S&P / 11.30% |
WinQNCX / S&P 1396.20% / 27.70% |
| 2025-Q42/2 |
WinQNCX / S&P 105.52% / 2.65% |
No dataQNCX / S&P / 9.00% |
WinQNCX / S&P 5486.26% / 13.40% |
| 2025-Q31/2 |
LoseQNCX / S&P -1.21% / 8.12% |
No dataQNCX / S&P / 4.61% |
WinQNCX / S&P 5762.90% / 13.45% |
| 2025-Q22/2 |
WinQNCX / S&P 24.06% / 10.94% |
No dataQNCX / S&P / 4.83% |
WinQNCX / S&P 5660.32% / 10.63% |
| 2025-Q11/2 |
LoseQNCX / S&P -28.88% / -4.27% |
No dataQNCX / S&P / 4.98% |
WinQNCX / S&P 488.16% / 10.57% |
| 2024-Q42/2 |
WinQNCX / S&P 140.98% / 2.41% |
No dataQNCX / S&P / 5.25% |
WinQNCX / S&P 55.95% / 6.15% |
| 2024-Q31/2 |
LoseQNCX / S&P 3.47% / 5.89% |
No dataQNCX / S&P / 5.89% |
WinQNCX / S&P 63.16% / 6.11% |
| 2024-Q21/2 |
LoseQNCX / S&P -29.25% / 4.28% |
No dataQNCX / S&P / 5.38% |
WinQNCX / S&P 51.81% / 5.12% |
| 2024-Q10/2 |
LoseQNCX / S&P 0.95% / 10.56% |
No dataQNCX / S&P / 5.71% |
LoseQNCX / S&P -36.67% / 5.59% |
| 2023-Q40/2 |
LoseQNCX / S&P -6.25% / 11.69% |
No dataQNCX / S&P / 6.81% |
LoseQNCX / S&P -46.84% / 7.78% |
| 2023-Q30/2 |
LoseQNCX / S&P -25.58% / -3.27% |
No dataQNCX / S&P / 7.52% |
LoseQNCX / S&P -65.92% / -5.03% |
| 2023-Q20/2 |
LoseQNCX / S&P -3.53% / 8.74% |
No dataQNCX / S&P / 9.50% |
LoseQNCX / S&P -69.71% / -8.57% |
| 2023-Q11/2 |
WinQNCX / S&P 144.90% / 7.50% |
No dataQNCX / S&P / 10.77% |
LoseQNCX / S&P -59.60% / -15.69% |
| 2022-Q40/1 |
LoseQNCX / S&P -52.11% / 7.56% |
No dataQNCX / S&P / 11.88% |
No dataQNCX / S&P / -17.99% |
| 2022-Q30/1 |
LoseQNCX / S&P -40.09% / -4.88% |
No dataQNCX / S&P / 13.47% |
No dataQNCX / S&P / -1.41% |
| 2022-Q20/1 |
LoseQNCX / S&P -64.14% / -16.10% |
No dataQNCX / S&P / 13.71% |
No dataQNCX / S&P / 11.04% |
| 2022-Q10/1 |
LoseQNCX / S&P -50.95% / -4.60% |
No dataQNCX / S&P / 15.97% |
No dataQNCX / S&P / 42.23% |
| 2021-Q40/1 |
LoseQNCX / S&P -86.23% / 11.03% |
No dataQNCX / S&P / 15.00% |
No dataQNCX / S&P / 96.40% |
| 2021-Q31/1 |
WinQNCX / S&P 72.94% / 0.58% |
No dataQNCX / S&P / 10.77% |
No dataQNCX / S&P / 69.42% |
| 2021-Q21/1 |
WinQNCX / S&P 47.10% / 8.55% |
No dataQNCX / S&P / 6.58% |
No dataQNCX / S&P / 51.81% |
| 2021-Q11/1 |
WinQNCX / S&P 29.70% / 6.17% |
No dataQNCX / S&P / -1.06% |
No dataQNCX / S&P / 7.39% |
| 2020-Q40/1 |
LoseQNCX / S&P -44.44% / 12.15% |
No dataQNCX / S&P / -3.72% |
No dataQNCX / S&P / -33.42% |
| 2020-Q30/1 |
LoseQNCX / S&P 7.99% / 8.93% |
No dataQNCX / S&P / -2.04% |
No dataQNCX / S&P / -27.10% |
| 2020-Q20/1 |
LoseQNCX / S&P 1.51% / 20.54% |
No dataQNCX / S&P / -0.46% |
No dataQNCX / S&P / -27.11% |
| 2020-Q11/1 |
WinQNCX / S&P -18.76% / -19.60% |
No dataQNCX / S&P / 3.47% |
No dataQNCX / S&P / -14.75% |
| 2019-Q41/1 |
WinQNCX / S&P 125.19% / 9.07% |
No dataQNCX / S&P / 5.36% |
No dataQNCX / S&P / 2.99% |
| 2019-Q30/1 |
LoseQNCX / S&P -41.35% / 1.70% |
No dataQNCX / S&P / 5.02% |
No dataQNCX / S&P / 0.21% |
| 2019-Q20/0 |
No dataQNCX / S&P / 4.30% |
No dataQNCX / S&P / 6.64% |
No dataQNCX / S&P / 8.65% |
| 2019-Q10/0 |
No dataQNCX / S&P / 13.65% |
No dataQNCX / S&P / 8.12% |
No dataQNCX / S&P / 14.29% |
| 2018-Q40/0 |
No dataQNCX / S&P / -13.52% |
No dataQNCX / S&P / 9.05% |
No dataQNCX / S&P / 18.23% |
| 2018-Q30/0 |
No dataQNCX / S&P / 7.71% |
No dataQNCX / S&P / 10.21% |
No dataQNCX / S&P / 19.06% |
| 2018-Q20/0 |
No dataQNCX / S&P / 3.43% |
No dataQNCX / S&P / 9.03% |
No dataQNCX / S&P / 14.46% |
| 2018-Q10/0 |
No dataQNCX / S&P / -0.76% |
No dataQNCX / S&P / 7.68% |
No dataQNCX / S&P / 12.46% |
| 2017-Q40/0 |
No dataQNCX / S&P / 6.64% |
No dataQNCX / S&P / 7.03% |
No dataQNCX / S&P / 13.82% |
| 2017-Q30/0 |
No dataQNCX / S&P / 4.48% |
No dataQNCX / S&P / 5.68% |
No dataQNCX / S&P / 17.57% |
| 2017-Q20/0 |
No dataQNCX / S&P / 3.09% |
No dataQNCX / S&P / 4.83% |
No dataQNCX / S&P / 17.74% |
| 2017-Q10/0 |
No dataQNCX / S&P / 6.07% |
No dataQNCX / S&P / 3.67% |
No dataQNCX / S&P / 13.32% |
| 2016-Q40/0 |
No dataQNCX / S&P / 3.82% |
No dataQNCX / S&P / 2.09% |
No dataQNCX / S&P / 7.05% |
| 2016-Q30/0 |
No dataQNCX / S&P / 3.85% |
No dataQNCX / S&P / 0.20% |
No dataQNCX / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | QNCX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -89.84% | 20.78% |
| Annualized return | -89.84% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | QNCX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.83% | 83.14% |
| Annualized return | -72.06% | 12.86% |
10Y · 2019-05-09 to 2026-08-27
| Metric | QNCX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.51% | 319.30% |
| Annualized return | -41.20% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |